Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SHR7280

Phase 3Small molecule

JJiangsu HengRui Medicine Co., Ltd.

SHR7280 is one of 15 small molecule programs targeting Uterine Fibroid. It is currently in Phase 3.

1

Indications

10

Total Trials

1

Active Trials

14

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uterine FibroidRecruiting

Uterine FibroidPhase 3

Recruiting

Competition

Competitive Landscape

18 competitors in Uterine Fibroid

#DrugCompanyPhaseTrials

Orilissa

Femara

Lupron

Sun Pharmaceutical Industries, Inc.

Mifeprex

Cytotec

Cyklokapron

Zoladex

TTerSera Therapeutics LLC

Acetadote

AArbor Pharmaceuticals, Inc.

Esbriet

LLegacy Health System

Orgovyx

Sumitomo Pharma America, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Efficacy and Safety1 trial

To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT05994378·317 enrolled

Endometriosis1 trial

The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis.

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1/2·NCT04417972·179 enrolled

Uterine Fibroid1 trial

A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2/3·NCT05442827·357 enrolled

Assisted Reproductive Technology1 trial

Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT05082233·85 enrolled

Midazolam1 trial

A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT06949124·20 enrolled

5 more indications

Trial1 trial

A Trial of SHR7280 in Healthy Subjects

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT06969664·16 enrolled

Adult1 trial

A Study to Evaluate the Mass Balance of [14C]SHR7280 in Healthy Adult Volunteers

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT06408948·6 enrolled

PK/PD1 trial

The PK/PD Study of SHR7280 Tablets in Healthy Subjects.

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04554043·118 enrolled

Prostate Cancer1 trial

A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04995042·12 enrolled

Unspecified1 trial

A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT05868057·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for SHR7280. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SHR7280 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SHR7280. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu HengRui Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu HengRui Medicine Co., Ltd.

Related News